{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:41:06Z","timestamp":1793677266220,"version":"4.5.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lpm.2025.104330","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T23:37:53Z","timestamp":1763854673000},"page":"104330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Update on dermatological toxicities of immune checkpoint inhibitors"],"prefix":"10.1016","volume":"55","author":[{"given":"Davide","family":"Fattore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lauletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Pages","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Theret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lpm.2025.104330_bib0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1615\/CritRevImmunol.2023047032","article-title":"Autoimmune skin diseases and immune checkpoint inhibitors","volume":"42","author":"Fattore","year":"2022","journal-title":"Crit Rev Immunol"},{"issue":"5","key":"10.1016\/j.lpm.2025.104330_bib0002","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"issue":"Pt 2","key":"10.1016\/j.lpm.2025.104330_bib0003","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.semcancer.2022.03.020","article-title":"The evolutionary legacy of immune checkpoint inhibitors","volume":"86","author":"Kaushik","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.lpm.2025.104330_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217616","article-title":"Clinical development of immuno-oncology therapeutics","volume":"617","author":"Wang","year":"2025","journal-title":"Cancer Lett"},{"issue":"Suppl 7","key":"10.1016\/j.lpm.2025.104330_bib0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lpm.2025.104330_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115053","article-title":"Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1: seasonal variation and association with outcome","volume":"212","author":"Jurlander","year":"2024","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.lpm.2025.104330_bib0007","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.lpm.2025.104330_bib0008","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.lpm.2025.104330_bib0009","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"10.1016\/j.lpm.2025.104330_bib0010","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2024.01.038","article-title":"Timing of cutaneous immune-related adverse events impacts survival in patients with cancer treated with immune-checkpoint inhibitors: a multi-institutional cohort study","volume":"90","author":"Rashdan","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.lpm.2025.104330_bib0011","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.jid.2022.04.020","article-title":"Cutaneous toxicities associated with immune checkpoint inhibitors: an observational, pharmacovigilance study","volume":"142","author":"Le","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.lpm.2025.104330_bib0012","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/ced\/llaf173","article-title":"Grade 3 and grade 4 cutaneous toxicities in patients across multiple solid tumour types receiving checkpoint inhibitor therapy: an observational study. The experience of a single large specialist institution","volume":"50","author":"Sharif","year":"2025","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"10.1016\/j.lpm.2025.104330_bib0013","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.lpm.2025.104330_bib0014","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.lpm.2025.104330_bib0015","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaad.2025.02.080","article-title":"Nivolumab\/relatlimab-associated cutaneous immune-related adverse events in patients treated for advanced melanoma: a multicenter retrospective cohort study","volume":"93","author":"Hijaz","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.lpm.2025.104330_bib0016","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2020.09.096","article-title":"Impact of ethnicity on the diagnosis and management of cutaneous toxicities from immune checkpoint inhibitors","volume":"84","author":"Thompson","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0017","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jaad.2021.06.885","article-title":"Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: a retrospective cohort study","volume":"87","author":"Bui","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.lpm.2025.104330_bib0018","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jaad.2023.02.014","article-title":"Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy","volume":"88","author":"Nguyen","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.lpm.2025.104330_bib0019","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1111\/jdv.20484","article-title":"Seasonal and geographic variation in cutaneous immune-related adverse events after treatment with immune checkpoint inhibitors","volume":"39","author":"Rajeh","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.lpm.2025.104330_bib0020","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.semarthrit.2021.03.004","article-title":"The role of PTPN22 in the pathogenesis of autoimmune diseases: a comprehensive review","volume":"51","author":"Tizaoui","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.lpm.2025.104330_bib0021","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s00432-021-03811-3","article-title":"Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients","volume":"148","author":"Verkhovskaia","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.lpm.2025.104330_bib0022","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.lpm.2025.104330_bib0023","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2019.0046","article-title":"Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma","volume":"5","author":"Quach","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.lpm.2025.104330_bib0024","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study","volume":"79","author":"Min Lee","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.lpm.2025.104330_bib0025","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jaad.2019.12.068","article-title":"Bullous pemphigoid after anti-programmed death-1 therapy: a retrospective case-control study evaluating impact on tumor response and survival outcomes","volume":"87","author":"Nelson","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0026","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2025.104330_bib0027","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.lpm.2025.104330_bib0028","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5415\/apallergy.0000000000000146","article-title":"From tumor to tolerance: a comprehensive review of immune checkpoint inhibitors and immune-related adverse events","volume":"14","author":"Sutanto","year":"2024","journal-title":"Asia Pac Allergy"},{"issue":"11","key":"10.1016\/j.lpm.2025.104330_bib0029","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","article-title":"CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential","volume":"55","author":"Koh","year":"2023","journal-title":"Exp Mol Med"},{"issue":"19","key":"10.1016\/j.lpm.2025.104330_bib0030","first-page":"32650","article-title":"BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors","volume":"S0190-9622","author":"Hasan Ali","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.lpm.2025.104330_bib0031","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s43556-025-00272-9","article-title":"Autoimmune bullous diseases: pathogenesis and clinical management","volume":"6","author":"Feng","year":"2025","journal-title":"Mol Biomed"},{"issue":"30","key":"10.1016\/j.lpm.2025.104330_bib0032","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.lpm.2025.104330_bib0033","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1158\/1078-0432.CCR-23-3431","article-title":"Immunologic profiling of immune-related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways","volume":"30","author":"Lacouture","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.lpm.2025.104330_bib0034","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S1470-2045(18)30828-3","article-title":"New therapeutic perspectives to manage refractory immune checkpoint-related toxicities","volume":"20","author":"Martins","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.lpm.2025.104330_bib0035","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.lpm.2025.104330_bib0036","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors","volume":"107","author":"Hasan Ali","year":"2019","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.lpm.2025.104330_bib0037","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.21037\/atm-20-6427","article-title":"The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer","volume":"9","author":"Naqash","year":"2021","journal-title":"Ann Transl Med"},{"issue":"3","key":"10.1016\/j.lpm.2025.104330_bib0038","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","article-title":"Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1","volume":"28","author":"McCulloch","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.lpm.2025.104330_bib0039","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/bjd.21781","article-title":"Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the european academy of dermatology and venereology task force of dermatology for cancer patients","volume":"187","author":"Nikolaou","year":"2022","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.lpm.2025.104330_bib0040","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/jdv.17855","article-title":"European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement","volume":"36","author":"Apalla","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.lpm.2025.104330_bib0041","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0042","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jamadermatol.2018.4560","article-title":"Clinical characterization of immunotherapy-related pruritus among patients seen in 2 oncodermatology clinics","volume":"155","author":"Phillips","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.lpm.2025.104330_bib0043","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.det.2018.02.010","article-title":"Pruritus associated with targeted anticancer therapies and their management","volume":"36","author":"Wu","year":"2018","journal-title":"Dermatol Clin"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0044","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaad.2020.05.045","article-title":"Management of immune checkpoint inhibitor-induced bullous pemphigoid","volume":"84","author":"Apalla","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0045","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2023.10.012","article-title":"Use of omalizumab is associated with improvement of pruritic skin disorders induced by immune checkpoint inhibitors: a retrospective cohort from the European task force of dermatology for cancer patients","volume":"90","author":"Alamon-Reig","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.lpm.2025.104330_bib0046","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.annonc.2021.04.007","article-title":"IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy","volume":"32","author":"Gutzmer","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.lpm.2025.104330_bib0047","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.annonc.2021.02.016","article-title":"IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies","volume":"32","author":"Barrios","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lpm.2025.104330_bib0048","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2147\/CCID.S511559","article-title":"Effectiveness and safety of dupilumab and tralokinumab for treating atopic dermatitis and pruritic skin disorders in oncological patients: a narrative review","volume":"18","author":"Lauletta","year":"2025","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"10.1016\/j.lpm.2025.104330_bib0049","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010638","article-title":"Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events","volume":"13","author":"Khattab","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.lpm.2025.104330_bib0050","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2147\/JAA.S474411","article-title":"Tralokinumab for the treatment of adult atopic dermatitis in special populations","volume":"17","author":"Potestio","year":"2024","journal-title":"J Asthma Allergy"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0051","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0052","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/biomedicines11020323","article-title":"A review of bullous dermatologic adverse events associated with anti-cancer therapy","volume":"11","author":"Parisi","year":"2023","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.lpm.2025.104330_bib0053","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/CMR.0000000000000819","article-title":"Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases","volume":"32","author":"Ingen-Housz-Oro","year":"2022","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0054","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000877","article-title":"Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases","volume":"33","author":"Ingen-Housz-Oro","year":"2023","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.lpm.2025.104330_bib0055","doi-asserted-by":"crossref","first-page":"ltac016","DOI":"10.1093\/immadv\/ltac016","article-title":"Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors","volume":"2","author":"Jfri","year":"2022","journal-title":"Immunother Adv"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0056","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14830","article-title":"Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors","volume":"34","author":"Cutroneo","year":"2021","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0057","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jaad.2023.09.070","article-title":"Onset of psoriasis with immune checkpoint inhibitor therapy: a systematic review","volume":"90","author":"Tarafdar","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.lpm.2025.104330_bib0058","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","article-title":"Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European network for cutaneous adverse event to oncologic drugs (ENCADO) group","volume":"84","author":"Nikolaou","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.lpm.2025.104330_bib0059","first-page":"e254","article-title":"Groupe de Recherche sur le Psoriasis and the Groupe Canc\u00e9rologie Cutan\u00e9e of the Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie the GEM Resopso, Apsoderm and the Groupe Fran\u00e7ais de Pneumo-Canc\u00e9rologie. Anti-PD1-induced psoriasis: a study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.lpm.2025.104330_bib0060","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.abd.2023.09.003","article-title":"Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors","volume":"99","author":"Wan","year":"2024","journal-title":"An Bras Dermatol"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0061","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jaad.2022.02.030","article-title":"Treatment of immune checkpoint inhibitor-mediated psoriasis: a systematic review","volume":"87","author":"Said","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.lpm.2025.104330_bib0062","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3390\/ph16111548","article-title":"IL12\/23 blockade with ustekinumab as a treatment for immune-related cutaneous adverse events","volume":"16","author":"Gu","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"10.1016\/j.lpm.2025.104330_bib0063","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.3390\/jcm13071940","article-title":"Biological therapy for psoriasis in cancer patients: an 8-year retrospective real-life study","volume":"13","author":"Battista","year":"2024","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.lpm.2025.104330_bib0064","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/jdv.20809","article-title":"Systemic treatment of immune checkpoint inhibitor-induced psoriasis: inference-based guidance","volume":"39","author":"Papp","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.lpm.2025.104330_bib0065","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0066","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaad.2019.06.035","article-title":"Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events","volume":"82","author":"Chan","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.lpm.2025.104330_bib0067","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1111\/jdv.14284","article-title":"Oral lichenoid reactions associated with anti-PD-1\/PD-L1 therapies: clinicopathological findings","volume":"31","author":"Sibaud","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0068","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamadermatol.2024.5136","article-title":"Immune checkpoint inhibitor-induced vitiligo-like depigmentation","volume":"161","author":"Starace","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.lpm.2025.104330_bib0069","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.anai.2021.02.009","article-title":"Immune-related cutaneous adverse events due to checkpoint inhibitors","volume":"126","author":"Wang","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.lpm.2025.104330_bib0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jdin.2021.09.002","article-title":"Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: a cross-sectional study","volume":"5","author":"Dousset","year":"2021","journal-title":"JAAD Int"},{"issue":"1","key":"10.1016\/j.lpm.2025.104330_bib0071","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.lpm.2025.104330_bib0072","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamadermatol.2022.0354","article-title":"Risk factors for the development of bullous pemphigoid in US patients receiving immune checkpoint inhibitors","volume":"158","author":"Said","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.lpm.2025.104330_bib0073","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1111\/jdv.17253","article-title":"Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1\/PD-L1 therapy: a national retrospective study","volume":"35","author":"Juzot","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.lpm.2025.104330_bib0074","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007324","article-title":"Management of immune-related cutaneous adverse events with dupilumab","volume":"11","author":"Kuo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.lpm.2025.104330_bib0075","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2019.08.030","article-title":"Nivolumab-related mucous membrane pemphigoid","volume":"121","author":"Sibaud","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.lpm.2025.104330_bib0076","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14171","article-title":"Alopecia areata as an immune-related adverse event of immune checkpoint inhibitors: a review","volume":"33","author":"Antoury","year":"2020","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.lpm.2025.104330_bib0077","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjd.15237","article-title":"Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors","volume":"176","author":"Zarbo","year":"2017","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.lpm.2025.104330_bib0078","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/intimm\/dxz039","article-title":"Pathomechanisms of immune-mediated alopecia","volume":"31","author":"Anzai","year":"2019","journal-title":"Int Immunol"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0079","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.annder.2022.11.012","article-title":"Oral mucosal toxicities induced by immune checkpoint inhibitors: clinical features and algorithm management","volume":"150","author":"Vigarios","year":"2023","journal-title":"Ann Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0080","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/scd.12887","article-title":"Lesions in the oral mucosa associated with the use of checkpoint inhibitors: a bibliometric and critical review","volume":"44","author":"Jural","year":"2024","journal-title":"Spec Care Dentist"},{"issue":"11","key":"10.1016\/j.lpm.2025.104330_bib0081","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/cncr.33436","article-title":"Oral side effects of immune checkpoint inhibitor therapy (ICIT): an analysis of 4683 patients receiving ICIT for malignancies at MA General Hospital, Brigham & Women's Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019","volume":"127","author":"Xu","year":"2021","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.lpm.2025.104330_bib0082","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0083","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1634\/theoncologist.2019-0467","article-title":"Sicca syndrome induced by immune checkpoint inhibitor therapy: optimal management still pending","volume":"25","author":"Ortiz Brugu\u00e9s","year":"2020","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.lpm.2025.104330_bib0084","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/1744666X.2024.2370327","article-title":"Sicca syndrome\/Sj\u00f6gren's disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management","volume":"20","author":"Pasoto","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.rdc.2024.01.007","article-title":"De novo connective tissue disorders as immune-related adverse events","volume":"50","author":"Cho","year":"2024","journal-title":"Rheum Dis Clin North Am"},{"issue":"7","key":"10.1016\/j.lpm.2025.104330_bib0086","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.revmed.2025.05.004","article-title":"Immune checkpoint inhibitor-related eosinophilic fasciitis: 3 case reports with literature review","volume":"46","author":"Biteau","year":"2025","journal-title":"Rev Med Interne"},{"issue":"1","key":"10.1016\/j.lpm.2025.104330_bib0087","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaad.2024.03.015","article-title":"Characteristics and management of sclerosing skin diseases during immune checkpoint inhibitor therapy: an evidence-based review","volume":"91","author":"Sood","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.lpm.2025.104330_bib0088","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1136\/annrheumdis-2018-213677","article-title":"Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1","volume":"78","author":"Michot","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.lpm.2025.104330_bib0089","first-page":"75","article-title":"The cancer immunotherapy environment may confound the utility of anti-TIF-1\u03b3 in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature","volume":"24","author":"Zarkavelis","year":"2020","journal-title":"Contemp Oncol (Pozn)"},{"issue":"1","key":"10.1016\/j.lpm.2025.104330_bib0090","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13256-019-2105-9","article-title":"Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report","volume":"13","author":"Shibata","year":"2019","journal-title":"J Med Case Rep"},{"issue":"10","key":"10.1016\/j.lpm.2025.104330_bib0091","doi-asserted-by":"crossref","first-page":"e684","DOI":"10.1111\/jdv.17388","article-title":"Morphea-like changes in the setting of cancer immunotherapy","volume":"35","author":"De Simone","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.lpm.2025.104330_bib0092","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000525887","article-title":"Scleroderma-like syndrome in the setting of pembrolizumab therapy for non-small-cell lung cancer: diagnosis and dermatologic management","volume":"14","author":"Fattore","year":"2022","journal-title":"Case Rep Dermatol"},{"issue":"16","key":"10.1016\/j.lpm.2025.104330_bib0093","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025513","article-title":"Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: a case report","volume":"100","author":"Langan","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.lpm.2025.104330_bib0094","first-page":"267","article-title":"Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): immunologic reactions","author":"Zimmerman","year":"2019","journal-title":"Oncologic Critical Care"},{"issue":"4","key":"10.1016\/j.lpm.2025.104330_bib0095","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2340\/00015555-2566","article-title":"Development of papulopustular rosacea during nivolumab therapy for metastatic cancer","volume":"97","author":"Bousquet","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.lpm.2025.104330_bib0096","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jaad.2022.08.063","article-title":"Clinical characterization and treatment outcomes of follicular cutaneous immune-related adverse events caused by immune checkpoint inhibitors: a multicenter retrospective study","volume":"88","author":"Freites-Martinez","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.lpm.2025.104330_bib0097","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.jaad.2021.03.039","article-title":"Dermatologic infections in cancer patients treated with checkpoint inhibitors","volume":"85","author":"Do","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lpm.2025.104330_bib0098","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1537825","article-title":"Case report: acral vasculitis induced by immune checkpoint inhibitors: a case series and literature review","volume":"15","author":"Rivet","year":"2025","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.lpm.2025.104330_bib0099","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/jamadermatol.2025.0359","article-title":"Immune checkpoint inhibitor-induced lipodystrophy","volume":"161","author":"Riganti","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.lpm.2025.104330_bib0100","doi-asserted-by":"crossref","DOI":"10.5826\/dpc.1403a118","article-title":"The impact of immune checkpoint inhibitors-induced skin toxicities on patients quality of life and the role of dermatologic intervention","volume":"14","author":"Kemanetzi","year":"2024","journal-title":"Dermatol Pract Concept"},{"issue":"5","key":"10.1016\/j.lpm.2025.104330_bib0101","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamadermatol.2021.0326","article-title":"Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced cancer","volume":"157","author":"Thompson","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.lpm.2025.104330_bib0102","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1111\/jdv.20282","article-title":"Dermatologic immune-related adverse events: it is time for a game change!","volume":"39","author":"Fattore","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.lpm.2025.104330_bib0103","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jaad.2019.09.026","article-title":"Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: a retrospective cohort study","volume":"82","author":"Chen","year":"2020","journal-title":"J Am Acad Dermatol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498225000636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498225000636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:07:39Z","timestamp":1779923259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498225000636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0755498225000636"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2025.104330","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on dermatological toxicities of immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2025.104330","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104330"}}